Effect of Vaccination with Modified Vaccinia Ankara (ACAM3000) on Subsequent Challenge with Dryvax
Michael S. Seaman(Beth Israel Deaconess Medical Center), Raphael Dolin(Beth Israel Deaconess Medical Center), Stephen R. Walsh(Beth Israel Deaconess Medical Center), Lauren E. Grandpre(Beth Israel Deaconess Medical Center), Haesook T. Kim(Dana-Farber Cancer Institute), Lindsey R. Baden(Brigham and Women's Hospital), Marissa B. Wilck(Brigham and Women's Hospital), Lizanne C. Noble(Brigham and Women's Hospital), Kristen E. Stevenson(Dana-Farber Cancer Institute), Colleen Devoy(Beth Israel Deaconess Medical Center), Ayush Giri(Beth Israel Deaconess Medical Center), Jane A. Kleinjan(Brigham and Women's Hospital)
Cited by 39
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981
Influence of Human Immunodeficiency Virus Infection on the Course of Hepatitis C Virus Infection: A Meta‐Analysis
|Clinical Infectious Diseases|2001|969